Ocugen Inc., is a rapidly growing ophthalmology company developing an extensive clinical suite of innovative therapies designed to treat rare and deficient vision disorders. OCU300 received the first and only orphan eye graft drug from abroad, providing certain regulatory requirements and economic benefits.
Ocugen is also developing new biological treatments for retinitis pigmentosa (OCU100) and wet AMD (OCU200), as well as an innovative modifier gene therapy platform with potential to treat a wide range of inherited retinal diseases (OCU400).
